南方医科大学陈烨团队:丁酸盐或可延缓慢性肾病的进展
创作:aluba 审核:aluba 2019年11月20日
  • 纳入127名慢性肾病(CKD)患者及63名健康人,对比分析粪便及血清中的短链脂肪酸水平;
  • 健康人的血清短链脂肪酸水平显著高于CKD患者,CKD 5期(CKD5)患者的血清丁酸盐水平仅为健康人的一半;
  • 健康人的粪便丁酸盐水平显著高于CKD患者,并未CKD5患者的3倍之多,而CKD 1-4期患者的粪便丁酸盐水平也显著高于CKD5患者;
  • 丁酸盐水平与肾功能呈负相关;
  • CKD大鼠模型移植CKD患者的菌群,可通过增加TMAO的产生而加速CKD进展,补充丁酸盐可逆转。
主编推荐语
aluba
来自南方医科大学的陈烨团队在Clinical Science上发表的一项最新研究,发现慢性肾病患者的粪便及血清中的丁酸盐水平显著低于健康人,且5期患者的丁酸盐水平最低,丁酸盐水平与肾功能呈负相关。在慢性肾病大鼠模型中,补充丁酸盐可延缓慢性肾病的进展。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Clinical Science [IF:6.124]

Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease

短链脂肪酸(特别是丁酸盐)的降低促进慢性肾病的进展

10.1042/CS20190171

2019-09-10, Article

Abstract & Authors:展开

Abstract:收起
Chronic kidney disease (CKD) affects 10–15% of the population worldwide, results in high morbidity and mortality, and requires costly treatment and renal replacement therapy. Glomerulosclerosis, tubulointerstitial fibrosis, and persistent intestinal flora disturbance are common in CKD. Short-chain fatty acids (SCFAs), produced by the intestinal microbiota, have been previously reported to ameliorate kidney injury; however, the specific concentrations and types that are required to improve renal function remain unknown. The present study aims to evaluate the levels of SCFAs in healthy and CKD patients, and to test the hypothesis that SCFAs play a critical role in delaying CKD progression. One hundred and twenty-seven patients with CKD and 63 healthy controls from China were enrolled in the present study. Butyrate, which is considered beneficial to humans, was almost three-times higher in healthy volunteers than that in CKD5 subjects (P=0.001). Moreover, the serum SCFA levels in controls were significantly higher than that in CKD patients (P<0.05), and the butyrate level among CKD5 patients (1.48 ± 0.60 μmol/l) was less than half of that in controls (3.44 ± 2.12 μmol/l, P<0.001). In addition, we observed an inverse correlation between butyrate level and renal function (P<0.05). A CKD rat model transplanted with microbiota obtained from CKD patients exhibited accelerated CKD progression via increased production of trimethylamine N-oxide (TMAO), which was reversed by supplementation with extra butyrate. Our results showed that SCFA levels were reduced in CKD patients and that butyrate supplementation might delay CKD progression.

First Authors:
Siqi Wang,Dan Lv

Correspondence Authors:
Ye Chen

All Authors:
Siqi Wang,Dan Lv,Shuanghong Jiang,Jianpin Jiang,Min Liang,Fanfan Hou,Ye Chen

评论